A Phase 1 interventional study of HMPL-523 and Azacitidine in Acute Myeloid Leukemia, sponsored by Hutchison Medipharma Limited. Terminated at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2019-11-20.
Sponsored by Hutchison Medipharma Limited (part of HUTCHMED) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 265 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.
Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 403rd largest by enrollment of the 433 interventional ones that give a count, is one of 27 that started in 2018, is one of 121 in phase 1, and was the 61st registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →265 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18+
Beijing InnoCare Pharma Tech Co., Ltd. · Sites in China
Ages 18+
iCell Gene Therapeutics · Sites in China
Ages 18–70
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Sites in China
Ages 18+
Guangdong Second Provincial General Hospital · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
473 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 187 · Phase 2 191 · Phase 3 77 · Phase 4 13
First in 2003; this study’s year is marked. 27 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 50 across the 433 interventional studies, 100 across the 39 observational. Of the 72 that completed or were terminated, 9 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
115 of 473 have an industry lead sponsor. The 10 most frequent:
This study is registered under Hutchison Medipharma Limited, one of the names counted as HUTCHMED. Under that name alone:
Hutchison Medipharma Limited is the lead sponsor of 68 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 2 (22%) have results posted.
HUTCHMED has 4 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
71 of the studies in Leukemia, Myeloid, Acute with a site in China that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06802718Phase 3Peking University People's HospitalInterferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia | 2026-12 |
| NCT07712848Phase 3The Second Affiliated Hospital of Kunming Medical UniversityDEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML | 2026-12-01 |
| NCT07486479Phase 3The First Affiliated Hospital of Soochow UniversityVenetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | 2026-12-31 |
| NCT06990321Phase 3Yehui TanEffectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia | 2026-12-31 |
| NCT06345365Phase 3Zhongnan HospitalMA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | 2026-12-31 |
Add all 71 to your calendar (.ics) → With an account.
Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase I, open-label, non-randomized, multicenter study to evaluate the safety, pharmacokinetics and preliminary efficacy of HMPL-523 in combination with Azacitidine in previously untreated elderly patients with AML who are not eligible for standard induction therapy.
There are two stages in this study: a dose-escalation stage (stage 1) and a dose-expansion stage (stage 2).
Dose-escalation stage (stage 1):
The conventional 3+3 design (3 patients per dose cohort, with the potential to add additional 3 patients to the same cohort to further evaluate toxicity) will be applied for dose escalation and maximum tolerated dosage determination. Approximately 12 to 18 dose limited toxicities evaluable patients will be enrolled. A dose of HMPL-523 up to 800mg will be taken orally once daily continuously through a 28-day Cycle of study treatment. Azacitidine will be administered subcutaneously, beginning on Day 1 through Day 7 of each Cycle.
Dose-expansion stage (stage 2):
This phase is to further evaluate the safety, pharmacokinetics and preliminary efficacy of HMPL-523 in combination with Azacitidine in approximately 28 previously untreated elderly patients with AML. Patients will receive HMPL-523 in combination with Azacitidine in a 28-day cycle continuously until disease progression/relapse, death, or intolerable toxicity, whichever comes first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HMPL-523 will be taken orally once daily continuously through a 28-days Cycle of study treatment. Azacitidine will be administered subcutaneously, beginning on Day 1 through Day 7 of each Cycle.
Drug: HMPL-523 · Drug: Azacitidine
HMPL-523 tablet
Azacitidine Injection
Also known as: Vidaza
Adverse Event (AE) monitoring of HMPL-523 in combination with azacitidine
AE monitoring will be assessed by evaluation of study drug exposure, AEs , serious AEs, all deaths, as well as laboratory determinations and vital sign parameters.
Time frame: Measured from the first dose to within 30 days after the last dose.
Overall response rate (ORR)
Overall response rate will be defined as the proportion of subjects who achieve a complete remission (CR), complete remission incomplete (CRi), Morphologic leukemia-free state (MLFS), or partial remission(PR) per 2017 European Leukemia Net (ELN) recommendations
Time frame: Measured up to 1 year after the last subject has enrolled or all the subjects have finished their last EFS follow up, whichever comes first.
Maximum plasma concentration (Cmax) of HMPL-523
Maximum concentration, occurring at Tmax.
Time frame: Measured on the cycle 1 day 7, cycle 1 day 8, cycle 1 day 28 and cycle 2 day 1.
The time to Cmax (peak time, Tmax) of HMPL-523
The time at which maximum plasma concentration (Cmax) is observed.
Time frame: Measured on the cycle 1 day 7, cycle 1 day 8, cycle 1 day 28 and cycle 2 day 1.
The area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt) of HMPL-523
The area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration.
Time frame: Measured on the cycle 1 day 7, cycle 1 day 8, cycle 1 day 28 and cycle 2 day 1.
Half-life (t1/2) of HMPL-523
The time required for the concentration of the drug to reach half of its original value.
Time frame: Measured on the cycle 1 day 7, cycle 1 day 8, cycle 1 day 28 and cycle 2 day 1.
Clearance (CL) of Azacitidine
Clearance is defined as the rate at which drug is cleared from the blood.
Time frame: Measured on the cycle 1 day 7 and Cycle 1 day 8.
The area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt) of Azacitidine
The area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration.
Time frame: Measured on the cycle 1 day 7 and Cycle 1 day 8.
Half-life (t1/2) of Azacitidine
The time required for the concentration of the drug to reach half of its original value.
Time frame: Measured on the cycle 1 day 7 and Cycle 1 day 8.
Steady-state concentration(Css) of Azacitidine
The average concentration of drug at steady state
Time frame: Measured on the cycle 1 day 7 and Cycle 1 day 8.
Complete Remission Rate of Minimal Residual Disease (MRD) Negativity (CR MRD- rate)
CR MRD- rate will be defined as the proportion of subjects who achieve a CR and has a negative RT-qPCR or MFC at the same time.
Time frame: Measured up to 1 year after the last subject has enrolled or all the subjects have finished their last EFS follow up, whichever comes first.
Event Free Survival (EFS)
EFS will be defined as the number of days from the date of first dose to the date of earliest recurrence or PD or death.
Time frame: Measured up to 1 year after the last subject has enrolled or all the subjects have finished their last EFS follow up, whichever comes first.
Disease-free Survival (DFS)
DFS will be defined as the number of days from the date of composite complete response (CR + CRi) to the date of earliest recurrence or death.
Time frame: Measured up to 1 year after the last subject has enrolled or all the subjects have finished their last EFS follow up, whichever comes first.
Overall Survival (OS)
OS will be defined as the number of days from the date of enrollment to the date of death.
Time frame: Measured up to 1 year after the last subject has enrolled or all the subjects have finished their last EFS follow up, whichever comes first.
Cumulative incidence of relapse (CIR)
CIR will be defined as the cumulative proportion of subjects who has relapsed after achieving a composite complete response (CR + CRi).
Time frame: Measured up to 1 year after the last subject has enrolled or all the subjects have finished their last EFS follow up, whichever comes first.
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2018 to primary completion in Sep 2019, 11 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sovleplenib
Hutchison Medipharma Limited →